Universität zu Köln

Chen, Robert, Zinzani, Pier Luigi, Lee, Hun Ju, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Kim, Eunhee, Nahar, Akash, Balakumaran, Arun and Moskowitz, Craig H. (2019). Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood, 134 (14). S. 1144 - 1154. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

Programmed death-1 inhibitors are approved for patients with relapsed or refractory classic Hodgkin lymphoma (RRcHL). We present the 2-year follow-up of the phase 2 KEYNOTE-087 study of pembrolizumab in 210 patients, based on HL progression after autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV; cohort 1); salvage chemotherapy and BV, with ineligibility for SCT owing to chemorefractory disease (cohort 2); and progression after SCT without BV (cohort 3). With a median follow-up of 27.6 months, the objective response rate (ORR) by blinded independent central review was 71.9% (95% CI, 65.3-77.9), the complete response rate (CRR) was 27.6%, and the partial response (PR) rate was 44.3%. Median duration of response was 16.5months (range, 0.0+ to 27.0+ [+, no progressive disease at last assessment]) in all patients, 22.1months in cohort 1, 11.1 months in cohort 2, and 24.4 months in cohort 3. Median progression-free survival was not reached in all patients with CR: 13.8 months (95% CI, 12.0-22.1) for patients with PR and 10.9 months (95% CI, 5.6-11.1) for patients with stable disease. Median overall survival was not reached in all patients or in any cohort. Treatment-related adverse events (TRAEs) of any grade occurred in 153 (72.9%) patients; grades 3 and 4 occurred in 25 (12.0%) patients; none resulted in death. Results confirmed effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Chen, Robert UNSPECIFIED UNSPECIFIED UNSPECIFIED Zinzani, Pier Luigi UNSPECIFIED UNSPECIFIED UNSPECIFIED Lee, Hun Ju UNSPECIFIED UNSPECIFIED UNSPECIFIED Armand, Philippe UNSPECIFIED UNSPECIFIED UNSPECIFIED Johnson, Nathalie A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Brice, Pauline UNSPECIFIED UNSPECIFIED UNSPECIFIED Radford, John UNSPECIFIED UNSPECIFIED UNSPECIFIED Ribrag, Vincent UNSPECIFIED UNSPECIFIED UNSPECIFIED Molin, Daniel UNSPECIFIED UNSPECIFIED UNSPECIFIED Vassilakopoulos, Theodoros P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Tomita, Akihiro UNSPECIFIED UNSPECIFIED UNSPECIFIED von Tresckow, Bastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Shipp, Margaret A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lin, Jianxin UNSPECIFIED UNSPECIFIED UNSPECIFIED Kim, Eunhee UNSPECIFIED UNSPECIFIED UNSPECIFIED Nahar, Akash UNSPECIFIED UNSPECIFIED UNSPECIFIED Balakumaran, Arun UNSPECIFIED UNSPECIFIED UNSPECIFIED Moskowitz, Craig H. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-131421
DOI:	10.1182/blood.2019000324
Journal or Publication Title:	Blood
Volume:	134
Number:	14
Page Range:	S. 1144 - 1154
Date:	2019
Publisher:	AMER SOC HEMATOLOGY
Place of Publication:	WASHINGTON
ISSN:	1528-0020
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; MULTICOHORT; NIVOLUMAB; FAILURE Multiple languages Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/13142